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Abstract  
Since the identification of the proteinase-activated receptor (PAR) family as mediators of serine 
protease activity in the 1990’s, there has been tremendous progress in the elucidation of their 
pathophysiological roles.  The development of drugs that target PARs has been the focus of many 
laboratories for the potential treatment of thrombosis, cancer and other inflammatory diseases.  
Understanding the mechanisms of PAR activation and G protein signaling pathways evoked in response 
to the growing list of endogenous proteases has yielded great insight into receptor regulation at the 
molecular level. This has led to the development of new selective modulators of PAR activity, 
particularly PAR1.  The mixed success of targeting PARs has been best exemplified in the context of 
inhibiting PAR1 as a new antiplatelet therapy.  The development of the competitive PAR1 antagonist, 
vorapaxar (Zontivity), has clearly shown the value in targeting PAR1 in acute coronary syndrome (ACS); 
however the severity of associated bleeding with this drug has limited its use in the clinic.  Due to the 
efficacy of thrombin acting via PAR1, strategies to selectively inhibit specific PAR1-mediated G protein 
signaling pathways or to target the second thrombin platelet receptor, PAR4, are being devised.  The 
rationale behind these alternative approaches is to bias downstream thrombin activity via PARs to allow 
for inhibition of pro-thrombotic pathways but maintain other pathways that may preserve hemostatic 
balance and improve bleeding profiles for widespread clinical use.  This review summarizes the structural 
determinants that regulate PARs and the modulators of PAR activity developed to date.          
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  
Proteinase-activated receptors (PARs) are a family of G protein-coupled receptors (GPCR) that promote 
cellular activity in response to serine proteases in the body [1].  Four family members (PAR1-4) have been 
cloned [2-5]; the roles of which are as varied as the serine proteases that activate them.  Early studies 
delineating the process of PAR activation describe thrombin as the predominant protease for PAR1, PAR3 
and PAR4, whilst trypsin-related proteases preferentially target PAR2, and to a lesser extent, PAR4 [1].  Whilst 
these canonical proteases have been researched in great detail, a substantial number of non-canonical 
proteases that activate PARs have emerged and are in the early stages of investigation [6].  This review will 
primarily focus on the canonical activation of PARs by thrombin.  
 
Mechanisms of PAR cleavage and activation 
The protease-substrate recognition process is highly coordinated.  Serine proteases, such as thrombin, 
typically target substrates through the ability to recognize distinct amino acid residues, with preference for 
an arginine or lysine at position P1 and proline at P2 of the substrate cleavage site [7].  Evidence suggests that 
thrombin binding and cleavage of PARs involves the formation of a 3-dimensional structure between leucine 
residues in PAR1 (position P4) and PAR4 (position P5) and a putative proline residue in P2 of the cleavage site 
on the PAR N-terminus (Figure 1).  This aids recognition by thrombin to support receptor cleavage [8].  
Thrombin binding is also facilitated by the presence of a ‘hirudin-like’ domain distal to the cleavage site of 
PAR1 (D50KYEPFWEDEE) and PAR3 (F48 EEFP), which binds to the exosite I of thrombin  [9].  PAR4 lacks a 
hirudin-like thrombin binding domain [4] and requires higher concentrations of thrombin (5 nM) to elicit 
comparable half-maximal signaling responses (phosphatidylinositol hydrolysis) induced by thrombin via 
PAR1 (0.2 nM).  Thrombin-mediated cleavage of PAR4 is enhanced however through cooperation with PAR1 
and PAR3.  Both of these receptors serve as cofactors for thrombin to cleave and activate PAR4 [10, 11].  
Through the ability of PAR1 and PAR3 to bind to exosite I of thrombin, the active site within thrombin is then 
free for cleavage of adjacent substrates, such as PAR4.  This was first demonstrated using X-ray crystal 
structures of murine thrombin in complex with murine PAR3 and PAR4 extracellular regions [12].  Another 
study by Nieman and colleagues further delineated this mechanism in relation to PAR1- assisted cleavage of 
PAR4 by thrombin [11].  This study found that PAR1/PAR4 heterodimer formation is essential for PAR1-
assisted cleavage of PAR4.  The functional relevance of PAR cofactoring has recently been the topic of a 
comprehensive review by Trejo and colleagues [13].  The ability of PAR3 to cofactor PAR4 is essential for 
efficient murine platelet activation [10]. 
 
Following recognition, thrombin binds transiently to PAR1, PAR3 and PAR4 and irreversibly cleaves these 
receptors at the N-terminus prior to dissociation [14]. Proteolytic cleavage of the extracellular N-terminus 
results in the exposure of a unique tethered ligand. This tethered domain engages superficially with residues 
that comprise the extracellular loop 2 (ECL2) to promote self-activation and trigger signal transduction [15].  
Once proteolytic activation has taken place, PARs are terminally downregulated and require synthesis of 
fresh receptor to maintain responsiveness to extracellular proteases [16]. 
 
Synthetic peptides that mimic the tethered ligand domain for each PAR have been developed over the years 
[17].  These peptides bypass the cleavage process and bind directly to ECL2 regions to promote receptor 
activation.  Studies using synthetic PAR-selective peptide agonists and PAR knock out mice models have been 
valuable in elucidating the importance of PAR subtype activity in particular disease processes.  Well 
established roles for PARs include platelet activation that precedes thrombosis [18], cancer invasion and 
metastasis [19] and activation of pivotal pathways that promote acute and chronic inflammation (e.g. 
arthritis) [20]. 
 
 
PAR cleavage and non-PAR related activity 
PAR-independent effects have been reported for the 41 amino acid cleaved peptide derived from PAR1 [21]. 
This liberated region of PAR1 is referred to in the literature as parstatin (Figure 1).  Upon proteolytic 
unmasking of the PAR1 tethered ligand domain, parstatin is cleaved from the receptor and can act as a cell 
penetrable peptide to evoke pathways that modulate angiogenesis and renal ischemia in vitro [21, 22].  The 
functional capabilities of parstatin add to the diverse cellular activity possible upon proteolytic cleavage of 
PAR1.  Whether the cleaved peptide derived from other PAR family members display any efficacy remains to 
be determined.  Investigations into the protective role of parstatin in vivo are ongoing [23]. 
 
PAR Signaling  
The activation of PARs results in the stimulation of numerous intracellular signaling cascades.  Classical 
heterotrimeric guanine nucleotide-binding protein (G protein) dependent pathways downstream of PAR 
activation have been well characterized for each PAR subtype [24].  PAR1 and PAR2 functionally couple to 
multiple G proteins including the Gαq/11, Gαi/o, and Gα12/13 subfamilies [25-27].   Despite cleavage by 
thrombin, PAR3 does not signal conventionally via G proteins like the other PARs [10]. PAR3 can however 
enhance PAR1-Gα13 coupling through its ability to form a heterodimer with PAR1 [28].  There have been 
reports of IL-8 and ATP release downstream of thrombin-mediated PAR3 activation however direct 
coupling with specific G proteins remains unclear [29, 30].  Activation of PAR4 is reported to promote 
Gαq/11 and Gα12/13 mediated cellular responses [31, 32].  In addition to coupling to G proteins, PARs 
are known to signal via interaction with adapter proteins such as beta-arrestin 1 and 2 [33] and 
transactivation of receptor kinases such as EGFR [34].  
 
PAR Signaling – Ligand bias 
The signaling events that occur upon PAR activation will depend upon the protease involved, the cell type in 
which the PAR is expressed and the pathological context in question.   Signaling bias downstream of PAR 
activation has become a hot topic in recent years following the identification of new proteases capable of 
cleaving PARs [6, 35].  Indeed, the repertoire of proteases capable of regulating PAR activity is increasing 
rapidly (Table 1).  For example, activated protein-C (APC) can cleave PAR1 (R46) at a different site from 
thrombin (R41) and trigger an alternative signal cascade from thrombin  [36].  In contrast, other proteases can 
disarm PARs to render them inactive to canonical proteases.  A recent review by Hollenberg and colleagues 
eloquently summarized ligand-dependent biased signaling paradigms downstream of PAR activation [35].  
Whilst reviews conventionally cover previously published literature, this review used a combination of 
previously published adapted data sets and unpublished examples to illustrate biased signaling via PARs.  An 
example of PAR1 and PAR2 signaling bias was demonstrated using data sets comparing treatment with 
cockroach proteinase E1, neutrophil elastase (NE) and a biased PAR2 synthetic peptide, SLAAAA-NH2 
respectively. These activators were shown to preferentially activate Gα12/13-MAP kinase pathways but not 
beta-arrestin or Gαq-calcium signaling cascades.   Understanding the physiological relevance of these biased 
signaling pathways may help in effective regulation of PAR activity in the disease setting. 
 
PARs in disease – A focus on thrombosis 
One of the most researched areas of the PAR field is thrombin-mediated PAR activity in the cardiovascular 
system [18], in particular events downstream of PAR activation in platelets.  Thrombin is pivotal in the 
regulation of hemostasis and thrombosis during vascular injury [37].  The cellular effects of thrombin in this 
context have largely been attributed to PARs expressed on platelets.  In human platelets, PAR1 and PAR4 
function as a ‘dual receptor system’ to promote platelet activation in response to changing levels of local 
thrombin generated at the sites of injury [38].  The formation of a PAR1/PAR4 heterodimer has since been 
proposed [11, 18] however the requirement of thrombin in promoting dimerization has been disputed.  Early 
studies by Kuliopulos and colleagues demonstrated stable PAR1/PAR4 heterodimerization in recombinant 
cells systems which did not require thrombin cleavage [18].  Nieman and colleagues have since published a 
more detailed mechanism of PAR1/PAR4 dimer formation which details the essential role of thrombin 
cleavage in the promotion of heterodimerization [11].  In the latter investigation, heterodimer formation 
between PAR1 and PAR4 was only detected upon treatment with α-thrombin (10nM, 10mins).  The role of 
thrombin in this process was further demonstrated through inhibition of the exosite I of thrombin (where 
PAR1 binds).  Under these conditions, PAR1 and PAR4 were unable to form heterodimers.  Interestingly, 
PAR1 and PAR4 homodimerization was not influenced by thrombin.   
 
Activation of PAR1 triggers fast, transient signaling cascades whereas PAR4, due to lack of receptor 
desensitization, evokes slow and sustained signaling responses [39].  The signaling pathways activated in 
response to thrombin via PAR1 in platelets include Gαq/11, Gα12/13, and Gαi/o, whilst PAR4 couples to 
Gαq/11 and Gα12/13 but not Gαi/o [40, 41].  Together these pathways promote platelet shape change, 
aggregation and secretion prior to thrombus formation.  In the absence of PAR1 in mouse platelets, PAR4 
forms a heterodimer with PAR3 to promote thrombin-mediated platelet activity [10].  PAR3 does not 
mediate signal transduction upon thrombin cleavage, instead its role in platelets is merely to act as a cofactor 
to enable PAR4 to transmit signals in response to thrombin [42].  The development of PAR1 antagonists to 
inhibit thrombin-mediated platelet function as an alternative antiplatelet strategy has been the most 
progressive to date. 
 
PARs as antiplatelet targets 
Following many years of development, the first PAR1 competitive antagonist, vorapaxar (Zontivity), was 
approved for clinical use in the United States as an adjunctive antiplatelet therapy in the treatment of acute 
coronary syndromes [43].  Incidentally, the widespread clinical use of this drug has been limited due to the 
severity of associated bleeding and increased risk of intracranial hemorrhage in patient cohorts with acute 
coronary syndromes (ACS) [43].  Further investigations are required to understand the major bleeding profile.  
These include studies to assess dosing issues, genomic/proteomic interplay or combination therapies given to 
the patients enrolled in the clinical trials (i.e. P2Y12 antagonist/aspirin).  These factors may have contributed 
to the significant bleeding observed. The resolution of the PAR1-vorapaxar crystal structure has provided 
great insight into the vorapaxar binding site within PAR1 [15].  Unlike other GPCRs, which have deep binding 
pockets, vorapaxar binds with high affinity to the extracellular surface of PAR1 within a closed hydrophobic 
binding pocket. This closed binding mode explains the very slow dissociation rate (t1/2 = ~3hrs) of vorapaxar 
[44].  When combined with the long elimination of vorapaxar (t1/2 = 173-269 hours) [45], this might be one 
explanation for the severe bleeding observed in patient cohorts. The development of PAR1 antagonists with 
faster dissociation and elimination rates may hold the key to improving patient bleeding profiles. 
 
Non-competitive modulators of PAR activity 
As an alternative to competitive inhibition of GPCRs, Kuliopulos, Covic and colleagues have designed a series 
of cell-penetrating lipidated peptide mimetics called pepducins that purportedly target intracellular loops 
(ICLs) of GPCRs [46].  The use of pepducins designed to mimic ICL1 and ICL3 regions of PAR1 and PAR2 has 
been successful in the allosteric regulation of G protein signal transduction (Table 1).  Through this approach, 
selective PAR1 and PAR2 agonist and antagonist pepducins have been generated [46].  Recent interrogation 
of the binding properties of the ICL3 PAR1 agonist pepducin, P1pal-19 revealed direct interaction with helix 8 
(H8) of PAR1 [47].  In this study, activation of PAR1 by P1pal-19 involved the (D/N)PXXY motif in 
transmembrane-7 (TM7) and direct engagement with H8.  Binding of P1pal-19, in turn, altered the 
positioning ofTM6 into an open ‘on-state’ conformation to enhance PAR1-G protein coupling.  The specific 
binding properties of the other PAR pepducins have yet to be studied.  However, the PAR1 pepducin 
antagonist PZ-128 (P1pal-7) is currently in clinical trials as a potential antiplatelet agent in the treatment 
of cardiovascular disease.  Unlike vorapaxar, no adverse bleeding was reported when PZ-128 was tested 
in nonhuman primates [48].  Recent studies testing the clinical efficacy of PZ-128 in patients with 
vascular disease have now shown faster elimination rates with plasma levels of PZ-128 undetectable 
after 24 hours [49]. Whether this improves the bleeding severity and safety profile remains to be 
determined.  Unfortunately pepducins designed to target PAR4 activity, namely P4pal-10, also partially 
inhibit PAR1 [46].  More selective PAR4 pepducins are currently in development. 
 
The Flaumenhaft laboratory has also made progress in the development of small molecule PAR1 antagonists 
called parmodulins [50].  The parmodulin, ML-161, is a reversible allosteric PAR1 inhibitor that targets an 
intracellular region of the receptor.  In this manner, ML-161 is able to selectively inhibit PAR1-Gαq/11 
pathways whilst preserving Gα12/13 signaling in response to thrombin.  Parmodulins have shown great 
promise in PAR1 platelet function however their potential as an alternative antiplatelet therapy of clinical 
value has yet to be ascertained.  
 
Targeting PAR4 as an alternative approach 
Strategies to inhibit PAR4 activity have been less successful than those directed towards targeting PAR1 and 
PAR2 activity.  PAR4 is an important target as the inhibition of sustained platelet responses via thrombin-
PAR4 may offer another avenue to limit thrombin activity in the setting of thrombosis.  The only non-peptide 
antagonist that exists for PAR4 is YD-3.  This competitive PAR4 antagonist also weakly inhibits PAR1 activity in 
response to thrombin [51].  Furthermore, the actions of YD-3 may have limited use given recent data that 
showed platelets derived from patients harboring the rs773902 common variant (Ala120Thr) in the PAR4 
gene (F2RL3) do not show PAR4 inhibition to YD-3 treatment [52].  PAR4-mediated platelet aggregation 
measured from washed platelets derived from homozygous rs773902 donors was not subject to the same 
level of pharmacological inhibition by YD-3 when compared with control donors.  This PAR4 variant is more 
common in subjects of African ancestry therefore any future inhibitor derived from YD-3 may have 
limited use in this cohort of patients.  Selectivity seems to be the key issue when attempting to target PAR4.  
Clearly more information regarding the regulatory mechanisms that underlie PAR4 activity is required if 
progress is to be made.  PAR4 pharmacogenetic studies may reveal important structure-activity relationships 
that could help identify potentially targetable regions within PAR4, which in turn may aid the development of 
future PAR4 selective agents.  Such studies may help identify an alternative inhibitory strategy to develop 
effective antagonists for patients harboring the PAR4 Ala120Thr common variant. 
 
Conclusions and Perspectives  
Dual antiplatelet therapies (aspirin and the P2Y12 receptor inhibitor Clopidogrel) are commonly 
prescribed to ACS patients to minimize cardiovascular events such as thrombosis however not all 
patients tolerate these drugs.  Resistance to one or both of these drugs often results in recurrent 
thrombotic events. Failure of patients to respond to existing antiplatelet therapies is the reason why 
more drugs are being developed in this area.  PARs are obvious targets due to their role in regulating 
thrombin-mediated platelet function.  PAR-based treatments would offer an alternative way to inhibit 
platelet activation for those who do not respond to existing therapies.  The therapeutic potential of PAR 
modulators developed to date have been explored following canonical activation of PARs, however their 
effectiveness against the emerging non-canonical proteases will be equally important in determining 
their widespread use.  The mixed success of PAR1 competitive antagonists in the clinic has fueled 
development into alternative strategies to target PAR activity.  Whilst the approaches that offer 
allosteric regulation of PAR activity seem like an attractive therapeutic option, their success will not be 
known until the outcome of ongoing clinical trials [49]. 
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Figure 1:  Canonical cleavage of PARs  
Serine proteases such as thrombin or trypsin recognize and cleave PARs distinct residues that reside within 
the extracellular N-terminus.  The hirudin-like domain within PAR1 and PAR3 facilitate the recognition and 
thrombin-binding process. Proteolytic cleavage results in the liberation of part of the N-terminus to reveal a 
tethered ligand domain.  This tethered ligand region promotes ‘self-activation’ of PARs through superficial 
engagement with distinct residues that comprise the extracellular loop 2 (ECL2) domain.  Upon receptor 
activation, G protein and G protein-independent pathways are stimulated.  The signal transduction cascades 
that emanate from PARs following canonical activation have been characterized in the context of 
cardiovascular disease, inflammation and cancer.  PAR-independent roles for the liberated peptide, 
‘parstatin’, have also emerged.          
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 Table 1: Known agonists and antagonists of the PAR family  
*Biased PAR2 partial-agonist-antagonist, ** biased antagonist [22], ***selectivity issues – partial inhibition of PAR1 activity, Δbiased PAR2 agonist 
 
 PAR1 PAR2 PAR3 PAR4 
 
Gene Name F2R F2RL1 F2RL2 F2RL3 
G protein 
transduction  
Gαq/11, Gαi/o, Gα12/13 Gαq/11, Gαi/o,  Gα12/13 non-signaling receptor Gαq/11, Gαi/o 
Agonist 
proteases 
Thrombin 
Factor Xa 
Plasmin 
Activated protein C 
(APC) 
Matrix 
metalloproteinases 
(MMPs) - MMP1 and 
MMP13  
Elastase 
Proteinase 3 
Granzyme K 
Kallikreins (KLKs) –KLK4 
Trypsin 
Tryptase 
Factor VIIa 
Factor Xa (FXa) 
KLK2, KLK4, KLK14 
Neutrophil elastase 
Cathepsin S 
Gingipain 
Testisin 
Matriptase 
Thrombin 
APC 
FXa 
Thrombin 
Trypsin 
Plasmin 
Cathepsin G 
MASP1 
KLK14 
Disarming 
proteases 
Trypsin (at low 
concentrations) 
Cathepsin G 
Chymotrypsin 
Kallikreins (KLKs) – KLK14 
Implantation serine 
proteinase 2 (ISP2) 
Neutrophil elastase 
Cathepsin G 
Proteinase 3 
Elastolytic 
metalloproteinase (EPa) 
ISP2 
Neutrophil elastase 
Cathepsin G 
 
ISP2 
Selective 
agonists 
TFLLR-NH2 SLIGKV-NH2, SLIGRL-NH2, 
SLAAAA-NH2
Δ 
2-furoyl-LIGRLO-amide 
GB 110 
APC mimetics - P3RM, P3RL  GYPGKF-NH2, 
AYPGKF-NH2, 
AYPGKV-NH2, 
AYPGQV-NH2 
Selective 
antagonists 
SCH-530348 (Vorapaxar), 
SCH-79797 
E5555 (Atopaxar, in 
clinical trials) 
RWJ-56110 
ER-129614-06 
BMS-200261 
ML161 – Parmodulin2 
(allosteric) 
Q94 hydrochloride 
(allosteric) 
GB83, GB88* 
ENMD-1068 
K14585 
 tc-YGPKF 
YD-3 
Pepducin 
Agonists 
P1pal-19 
P1pal-13 
P2pal-21 (partial) 
P2pal-21F (also activates 
PAR1) 
  
Pepducin 
Antagonists 
P1pal-12, P2pal-12S,  
P4pal-10 (partial) 
PZ-128 (P1pal-7, in 
clinical trials) 
P2pal-18s**, 
P2pal-14GQ 
 P4pal-i1,  
P4pal-10*** 
Clinically used 
antagonists 
Vorapaxar    
 
